Exelixis Drug Patent Portfolio
Exelixis owns 2 orange book drugs protected by 13 US patents Given below is the list of Exelixis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141413 | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | 17 Apr, 2037 | Active |
| US9724342 | C-met modulator pharmaceutical compositions | 09 Jul, 2033 | Active |
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | 10 Feb, 2032 | Active |
| US12128039 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | 10 Feb, 2032 | Active |
| US9717720 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | 10 Feb, 2032 | Active |
| US10034873 | C-met modulator pharmaceutical compositions | 18 Jul, 2031 | Active |
| US10039757 | C-Met modulator pharmaceutical compositions | 18 Jul, 2031 | Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | 08 Oct, 2030 | Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | 15 Jan, 2030 | Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | 15 Jan, 2030 | Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | 15 Jan, 2030 | Active |
| US7579473 | c-Met modulators and methods of use | 14 Aug, 2026 | Active |
| US8497284 | C-met modulators and method of use | 24 Sep, 2024 | Expired |
Latest Legal Activities on Exelixis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Exelixis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2022 | US8877776 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2022 | US8877776 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Apr, 2022 | US11298349 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Apr, 2022 | US11298349 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Apr, 2022 | US11298349 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Apr, 2022 | US11298349 |
|
Email Notification
Critical
| 24 Mar, 2022 | US11298349 |
|
Email Notification
Critical
| 24 Mar, 2022 | US11298349 |
|
Issue Notification Mailed
Critical
| 23 Mar, 2022 | US11298349 |
|
Issue Notification Mailed
Critical
| 23 Mar, 2022 | US11298349 |
|
Application Is Considered Ready for Issue
Critical
| 18 Mar, 2022 | US11298349 |
|
Application Is Considered Ready for Issue
Critical
| 18 Mar, 2022 | US11298349 |
| Dispatch to FDC | 18 Mar, 2022 | US11298349 |
| Dispatch to FDC | 18 Mar, 2022 | US11298349 |
|
Email Notification
Critical
| 10 Mar, 2022 | US11298349 |
Exelixis's Drug Patent Litigations
Exelixis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 18, 2024, against patent number US11298349. The petitioner Azurity Pharmaceuticals, Inc., challenged the validity of this patent, with EXELIXIS, INC. as the respondent. Click below to track the latest information on how companies are challenging Exelixis's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US12128039 | January, 2025 |
Discretionary Denial
(02 Jul, 2025)
| EXELIXIS, INC. | Azurity Pharmaceuticals, Inc. |
| US11298349 | November, 2024 |
Institution Denied
(04 Jun, 2025)
| EXELIXIS, INC. | Azurity Pharmaceuticals, Inc. |
Exelixis Drug Patents' Oppositions Filed in EPO
Exelixis drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 05, 2013, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP10701175A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP12704492A | Aug, 2022 | STADA Arzneimittel AG | Revoked |
| EP11740764A | Jul, 2022 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP11740764A | Jul, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP11740764A | Jul, 2022 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10701175A | Dec, 2013 | Ladendorf, Oliver | Patent maintained as amended |
| EP10701175A | Dec, 2013 | Gallafent, Alison | Patent maintained as amended |
| EP10701175A | Dec, 2013 | Actavis Group PTC ehf | Patent maintained as amended |
Exelixis's Family Patents
Exelixis Drug List
Given below is the complete list of Exelixis's drugs and the patents protecting them.
1. Cabometyx
Cabometyx is protected by 12 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11141413 | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
17 Apr, 2037
(11 years from now)
| Active |
| US9724342 | C-met modulator pharmaceutical compositions |
09 Jul, 2033
(7 years from now)
| Active |
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(6 years from now)
| Active |
| US12128039 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(6 years from now)
| Active |
| US10034873 | C-met modulator pharmaceutical compositions |
18 Jul, 2031
(5 years from now)
| Active |
| US10039757 | C-Met modulator pharmaceutical compositions |
18 Jul, 2031
(5 years from now)
| Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
08 Oct, 2030
(4 years from now)
| Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
15 Jan, 2030
(3 years from now)
| Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(3 years from now)
| Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(3 years from now)
| Active |
| US7579473 | c-Met modulators and methods of use |
14 Aug, 2026
(6 months from now)
| Active |
| US8497284 | C-met modulators and method of use |
24 Sep, 2024
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cabometyx's drug page
2. Cometriq
Cometriq is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(6 years from now)
| Active |
| US12128039 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(6 years from now)
| Active |
| US9717720 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(6 years from now)
| Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
08 Oct, 2030
(4 years from now)
| Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
15 Jan, 2030
(3 years from now)
| Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(3 years from now)
| Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(3 years from now)
| Active |
| US7579473 | c-Met modulators and methods of use |
14 Aug, 2026
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cometriq's drug page